Immunotherapy News and Research

Latest Immunotherapy News and Research

New combination treatment offers hope for immune checkpoint blockade resistant skin cancers

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment.

2 Jun 2025

Adding immunotherapy to chemotherapy after surgery improves survival in colon cancer

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.

1 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.

1 Jun 2025

Combination treatment extends progression-free survival in advanced skin cancer

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

1 Jun 2025

Universal CAR T cell therapy shows promise for aggressive T cell cancers

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.

31 May 2025

Pitt professor wins NSF CAREER Award for AI-driven immunotherapy research

The University of Pittsburgh's Natasa Miskov-Zivanov, assistant professor of electrical and computer engineering, has received a prestigious Faculty Early Career Development (CAREER) Award of $581,503 from the National Science Foundation (NSF) for her project titled "Artificial Intelligence-Driven Framework for Efficient and Explainable Immunotherapy Design."

30 May 2025

TRR 417 initiative aims to unlock new treatments for colorectal cancer

In the realm of colorectal cancer treatments beyond surgery and radiation, one key question gained prominence in recent years: Is the tumor's DNA repair system defective, making it "microsatellite unstable"? Around 15 to 20 percent of all tumors have this trait, making them likely candidates for successful immunotherapy.

30 May 2025

TTF1 identified as key biomarker for advanced KRAS G12C-mutated non-small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib.

30 May 2025

New insights into decades-old bladder cancer treatment offers clues for immunotherapy

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer.

29 May 2025

Early allergen introduction reduces childhood food allergy risk

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic treatments in managing allergic conditions.

29 May 2025

New four drug combination sets new standard in myeloma care

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical Oncology, held May 30 through June 3 in Chicago.

29 May 2025

BCG immunotherapy reprograms bone marrow to boost cancer defense

29 May 2025

Innovative technology simplifies T cell harvesting for cancer immunotherapy

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce dramatic results when treating blood cancers like lymphoma and leukemia and shows promise against solid tumors.

29 May 2025

Wilms tumor found to contain millions of genetic changes

Researchers have uncovered that some childhood cancers have a substantially higher number of DNA changes than previously thought, changing the way we view children's tumours and possibly opening up new or repurposed treatment options.

29 May 2025

NCCN recognizes 2025 awardees for advancing global cancer care

The National Comprehensive Cancer Network (NCCN) announces 2025 awardees who go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.

28 May 2025

University of Houston receives $3 million to set up a Cancer Immunotherapy Biomarker Core

As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding groundbreaking projects, has awarded the University of Houston $3 million to set up a Cancer Immunotherapy Biomarker Core.

27 May 2025

ESMO releases updated scale to measure clinical benefit of cancer treatments

The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS (ESMO-Magnitude of Clinical Benefit Scale).

23 May 2025

Aging metabolism reduces effectiveness of CAR-T cell therapy

A Ludwig Cancer Research study has discovered that the metabolic decline that accompanies aging impairs the efficacy of CAR-T cell therapy, an immunotherapy in which T cells of the immune system are taken from patients, engineered to target cancer cells and reinfused into the same patients for treatment.

23 May 2025

New AI blood test tracks pancreatic cancer treatment response

An artificial intelligence technique for detecting DNA fragments shed by tumors and circulating in a patient's blood, developed by Johns Hopkins Kimmel Cancer Center investigators, could help clinicians more quickly identify and determine if pancreatic cancer therapies are working.

22 May 2025